Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 156 points (-1.1%) at 14,709 as of Monday, April 15, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 426 issues advancing vs. 2,527 declining with 106 unchanged. The Drugs industry currently sits down 2.11 versus the S&P 500, which is down 1.29. Top gainers within the industry include Sanofi ( SNY), up 2.5%, and GlaxoSmithKline ( GSK), up 1.9%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 2.75, Shire ( SHPG), down 2.13, Amgen ( AMGN), down 1.70, Biogen Idec ( BIIB), down 1.50 and Eli Lilly and Company ( LLY), down 0.71. TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today: 3. Theravance ( THRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Theravance is up $4.03 (16.96) to $27.79 on heavy volume Thus far, 3.3 million shares of Theravance exchanged hands as compared to its average daily volume of 984,200 shares. The stock has ranged in price between $25.26-$29.71 after having opened the day at $25.35 as compared to the previous trading day's close of $23.76. Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $2.3 billion and is part of the health care sector. Shares are up 4.9% year to date as of the close of trading on Friday. TheStreet Ratings rates Theravance as a sell. Among the areas we feel are negative, one of the most important has been very high debt management risk by most measures. Get the full Theravance Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.